Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of “Buy” by Brokerages

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have been given a consensus rating of “Buy” by the twelve research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and three have issued a strong buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $44.00.

A number of analysts have commented on DMRA shares. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Wedbush upped their target price on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 18th. Finally, Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price target for the company.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $40,000. Geode Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $266,000. Virtu Financial LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at $49,000. Sigma Planning Corp bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $334,000. Finally, Two Sigma Investments LP bought a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth $76,000. 14.20% of the stock is currently owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Stock Up 1.0%

Shares of Damora Therapeutics, Inc. Common Stock stock opened at $30.62 on Wednesday. The stock has a market cap of $1.89 billion, a P/E ratio of -9.09 and a beta of 1.47. Damora Therapeutics, Inc. Common Stock has a 12-month low of $2.45 and a 12-month high of $38.33. The business’s 50 day moving average is $28.70 and its 200-day moving average is $26.67.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.06. On average, sell-side analysts expect that Damora Therapeutics, Inc. Common Stock will post -1.98 EPS for the current year.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.